Detail

With the inauguration of its new site, Stallergenes continues its development and creates value in France

 

Antony (France), 24 May 2011 - Stallergenes S.A. announces the inauguration of its new administrative headquarters, located in Antony in the Hauts-de-Seine (92) area of France. Following the official opening of its grass pollen production site in Amilly (Loiret) in January, Stallergenes today inaugurated its new administrative headquarters in a ceremony attended by Patrick Devedjian, Member of Parliament and President of the Hauts-de-Seine Council, and Dr.
Isao Teshirogi, President and CEO of Shionogi & Co., Ltd, Stallergenes’ strategic ally in Japan, and President of the Japan Pharmaceutical Manufacturers Association (JPMA).

Initiated in 2009 and designed to meet the highest HQE/BBC environmental standards, this new section of the company’s head office, which will provide office space for an additional 200 employees, is intended specifically for administrative personnel and will enable the company to increase the space available for Research & Development.

Enjoying average annual growth of 14% – compared to 5% for the sector –, Stallergenes has quadrupled in size in the last 10 years and is now the 7th largest pharmaceutical company in France. The company has invested the fruits of this vigorous growth in both Research & Development of new products – with a cumulative investment since 2004 of 170 million euros – and its new industrial facilities – 30 million euros invested –. Stallergenes devotes around 20% of its annual turnover to Research & Development, amounting to 41 million euros in 2010, making it one of the top 10 pharmaceutical companies in France in terms of investment.

Between 2001 and 2011, the number of employees within the Group has risen from 400 to 1,000, and from 300 to 750 in Antony. In 2010 alone, the Group’s workforce grew by 12%, half of whom are top-level staff (at least 5 years of higher education).

“Our strong growth has allowed Stallergenes to pursue a business model based on innovation. Stallergenes’ shareholders have supported this model, in which profits are largely reinvested in the company. As an illustration of our expansion, our Antony site, which houses all our decisionmaking structures, has grown significantly in just a few years, with the continuous support of the town of Antony and the Hauts-de-Seine Council”, said Albert Saporta, Chairman and CEO of Stallergenes.

With direct operations in 10 countries, soon to be supplemented by the opening of 5 new subsidiaries, Stallergenes now conducts around 85% of its business in Europe. In parallel, the company signed an exclusive partnership agreement in September 2010 with Shionogi & Co. Ltd., one of the major pharmaceutical companies in Japan, for the development and marketing
of two sublingual allergen immunotherapy tablets resulting from the Stalair® program: Actair® house dust mite tablets and Japanese cedar pollen tablets. “We are delighted to have found in Stallergenes a strategic partner with whom we can strengthen our position in the allergy market in Japan”, stated Isao Teshirogi, President and CEO of Shionogi & Co., Ltd.

“Stallergenes is proof that it is possible to succeed in France by combining innovation and industry. Our role is to create the conditions for this performance," said Patrick Devedjian, Member of Parliament and President of the Hauts-de-Seine Council.

 

» Voor het VOLLEDIGE PERSBERICHT, klik hier.